Clinical Trials Logo

Mesothelioma; Pleura clinical trials

View clinical trials related to Mesothelioma; Pleura.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04300244 Active, not recruiting - Cancer Clinical Trials

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

NIPU
Start date: May 4, 2020
Phase: Phase 2
Study type: Interventional

The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.

NCT ID: NCT03907852 Active, not recruiting - Ovarian Cancer Clinical Trials

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Start date: April 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.